BioCurate enters into a commercial services relationship with the Walter and Eliza Hall Institute of Medical Research (WEHI)




June 14, 2017

BioCurate is a joint venture of the University of Melbourne and Monash University, supported by the Victorian State Government. This bold and important collaboration underpins BioCurate’s aim to address the key challenges in early stage drug development and to increase the number, quality and rate of translation of new drug discoveries into medically sound, commercially attractive, investable projects.

Last month Dr C. Glenn Begley returned from the USA to Melbourne and commenced as BioCurate’s CEO, building on a distinguished career as haematologist, oncologist and biotech CSO. Last week BioCurate officially opened its new premises at 407 Royal Parade.

BioCurate brings a commercial skill-set and extensive global industry experience to this joint venture. It is recognized that in order to achieve sector-wide change, scale and international partnering, there will be a need, over time, to engage more broadly with the commercial development of Melbourne’s life-sciences sector.

BioCurate is pleased to announce that as a first step towards this broader sector engagement, BioCurate has entered into a Commercial Services Agreement with WEHI, the Department of Medical Biology in the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne.

This Agreement covers the provision by BioCurate to WEHI for some specialist commercialization advice and contains all the standard commercial clauses relating to confidentiality and conflict of interest. The Board has determined that this advice will be provided by BioCurate’s CEO and will comprise around 2-4 days per month.

Dr Begley is a full-time employee of BioCurate with the requirements of the Company and its University Shareholders being his highest priority. Building on Dr Begley’s appointment, the Company will attract additional capability and continue to build expertise specifically targeted at early drug development.

BioCurate is committed to building on the combined research strengths of its University Shareholders to make transformational drug candidates become a reality.

Return to News